NZ712797A - Substituted aromatic compounds and related method for the treatment of fibrosis - Google Patents

Substituted aromatic compounds and related method for the treatment of fibrosis

Info

Publication number
NZ712797A
NZ712797A NZ712797A NZ71279714A NZ712797A NZ 712797 A NZ712797 A NZ 712797A NZ 712797 A NZ712797 A NZ 712797A NZ 71279714 A NZ71279714 A NZ 71279714A NZ 712797 A NZ712797 A NZ 712797A
Authority
NZ
New Zealand
Prior art keywords
fibrosis
alkenyl
alkyl
treatment
aromatic compounds
Prior art date
Application number
NZ712797A
Other languages
English (en)
Inventor
Lyne Gagnon
Pierre Laurin
Boulos Zacharie
Shaun Abbott
Brigitte Grouix
Original Assignee
Liminal Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liminal Biosciences Ltd filed Critical Liminal Biosciences Ltd
Publication of NZ712797A publication Critical patent/NZ712797A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • A61P33/12Schistosomicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C07C53/134Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
NZ712797A 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis NZ712797A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798269P 2013-03-15 2013-03-15
PCT/CA2014/000236 WO2014138906A1 (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Publications (1)

Publication Number Publication Date
NZ712797A true NZ712797A (en) 2020-08-28

Family

ID=51535669

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ712797A NZ712797A (en) 2013-03-15 2014-03-14 Substituted aromatic compounds and related method for the treatment of fibrosis

Country Status (25)

Country Link
US (3) US10023518B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970089B1 (cg-RX-API-DMAC7.html)
JP (1) JP6448562B2 (cg-RX-API-DMAC7.html)
KR (1) KR102196721B1 (cg-RX-API-DMAC7.html)
CN (2) CN110105200B (cg-RX-API-DMAC7.html)
AR (1) AR095429A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014231648B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022008A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905621C (cg-RX-API-DMAC7.html)
CL (1) CL2015002535A1 (cg-RX-API-DMAC7.html)
DK (1) DK2970089T3 (cg-RX-API-DMAC7.html)
EA (1) EA030651B1 (cg-RX-API-DMAC7.html)
ES (1) ES2741439T3 (cg-RX-API-DMAC7.html)
IL (1) IL241178B (cg-RX-API-DMAC7.html)
MX (1) MX379424B (cg-RX-API-DMAC7.html)
MY (1) MY180305A (cg-RX-API-DMAC7.html)
NZ (1) NZ712797A (cg-RX-API-DMAC7.html)
PH (1) PH12015502011B1 (cg-RX-API-DMAC7.html)
PL (1) PL2970089T3 (cg-RX-API-DMAC7.html)
PT (1) PT2970089T (cg-RX-API-DMAC7.html)
SG (1) SG11201507408XA (cg-RX-API-DMAC7.html)
TW (1) TWI689490B (cg-RX-API-DMAC7.html)
UY (1) UY35402A (cg-RX-API-DMAC7.html)
WO (1) WO2014138906A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507061B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
MY194308A (en) * 2014-10-10 2022-11-27 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compostions for the prevention and treatment of osteoporosis
WO2016074068A1 (en) * 2014-11-12 2016-05-19 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
JP6716598B2 (ja) * 2015-03-18 2020-07-01 ヴェクタス バイオシステムズ リミテッド 腎臓及び/又は肝臓疾患を治療するための組成物
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP3459539B1 (en) * 2016-05-19 2021-06-09 Everfront Biotech Inc. Pharmaceutical composition for delaying the onset of and/or treating pulmonary fibrosis
JP7214225B2 (ja) 2016-12-15 2023-01-30 タレンゲン インターナショナル リミテッド 脂肪肝を予防および治療するための方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR102126389B1 (ko) * 2018-09-14 2020-06-25 셀라이온바이오메드 주식회사 벤즈히드릴티오 아세트아미드 화합물을 유효성분으로 포함하는 간 질환의 예방 또는 치료용 조성물
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
CA3195137A1 (en) * 2020-10-06 2022-04-14 Lyne Gagnon Substituted aromatic compounds and pharmaceutical compositions thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183519A1 (en) * 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
CA2653262A1 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
WO2008112368A2 (en) * 2007-02-08 2008-09-18 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
HUE029126T2 (en) * 2009-05-04 2017-02-28 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical uses
ES2441800T3 (es) * 2009-05-04 2014-02-06 Prometic Biosciences Inc. Sales de ácido 3-pentilfenilacético y usos farmacéuticos de las mismas
AT509045B1 (de) * 2010-01-29 2011-06-15 Planta Naturstoffe Vertriebsges M B H Verbindungen zur behandlung von asthma bronchiale

Also Published As

Publication number Publication date
JP6448562B2 (ja) 2019-01-09
US11524930B2 (en) 2022-12-13
ZA201507061B (en) 2017-03-26
AU2014231648A1 (en) 2015-10-22
US20180237374A1 (en) 2018-08-23
IL241178A0 (en) 2015-11-30
US20200172462A1 (en) 2020-06-04
EA201591775A1 (ru) 2016-05-31
PL2970089T3 (pl) 2020-01-31
MX2015011878A (es) 2016-06-07
MY180305A (en) 2020-11-27
UY35402A (es) 2014-10-31
AR095429A1 (es) 2015-10-14
CA2905621C (en) 2021-06-29
CN110105200A (zh) 2019-08-09
CN105189438A (zh) 2015-12-23
KR20160051676A (ko) 2016-05-11
US20160039736A1 (en) 2016-02-11
CL2015002535A1 (es) 2016-03-28
WO2014138906A1 (en) 2014-09-18
PT2970089T (pt) 2019-09-04
US10023518B2 (en) 2018-07-17
TWI689490B (zh) 2020-04-01
TW201441186A (zh) 2014-11-01
US10550066B2 (en) 2020-02-04
EP2970089A4 (en) 2016-10-12
MX379424B (es) 2025-03-11
PH12015502011B1 (en) 2020-12-04
DK2970089T3 (da) 2019-08-05
EP2970089A1 (en) 2016-01-20
AU2014231648B2 (en) 2018-02-08
HK1220440A1 (en) 2017-05-05
SG11201507408XA (en) 2015-10-29
IL241178B (en) 2020-09-30
CN110105200B (zh) 2022-04-12
EA030651B1 (ru) 2018-09-28
JP2016512202A (ja) 2016-04-25
EP2970089B1 (en) 2019-05-08
CA2905621A1 (en) 2014-09-18
PH12015502011A1 (en) 2016-01-11
BR112015022008A2 (pt) 2021-05-25
ES2741439T3 (es) 2020-02-11
KR102196721B1 (ko) 2020-12-30

Similar Documents

Publication Publication Date Title
PH12015502011A1 (en) Substituted aromatic compounds and related method for the treatment of fibrosis
PH12015502012A1 (en) Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis
MX2022003032A (es) Oxinitruro de piridina, metodo para su preparacion y uso de este.
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
IN2014DN09352A (cg-RX-API-DMAC7.html)
IN2014DN09348A (cg-RX-API-DMAC7.html)
MX2017000612A (es) Inhibidores de tirosina quinasa del bazo (syk).
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
MD4666B1 (ro) Inhibitori ai Syk
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
WO2014099226A3 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
MX2014006366A (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
JOP20200024A1 (ar) مركبات ثنائي هيدروكساديازينون
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
WO2012131656A3 (en) Compounds for use as therapeutic agents affecting p53 expression and/or activity
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2018071315A3 (en) Piperidine derivatives as liver x receptor beta agonists, compositions, and their use
HK1242201A1 (en) Compositions and methods for treating cns disorders

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: PROMETIC PHARMA SMT LIMITED, GB

Effective date: 20160616

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY ANAQUA SERVICES

Effective date: 20210217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY ANAQUA SERVICES

Effective date: 20220218

LAPS Patent lapsed